Factors predictive of EFS including the type of BCR-ABL transcripts
| . | N . | Events . | Log-rank . | HR . | 95% CI HR . | P value . |
|---|---|---|---|---|---|---|
| Univariate* | ||||||
| TKI type | ||||||
| Imatinib 400† | 69 | 21 | 0.013 | |||
| Imatinib 800 | 199 | 38 | 0.58 | (0.34-0.99) | .045 | |
| Dasatinib | 104 | 7 | 0.28 | (0.12-0.67) | .004 | |
| Nilotinib | 108 | 11 | 0.45 | (0.22-0.95) | .035 | |
| Transcript type | ||||||
| e13a2‡ | 199 | 40 | 0.091 | |||
| e14a2 | 196 | 24 | 0.57 | (0.35-0.95) | .032 | |
| Both | 85 | 13 | 0.74 | (0.40-1.39) | .355 | |
| Splenomegaly (≥10 cm) | ||||||
| No | 453 | 68 | 0.012 | |||
| Yes | 27 | 9 | 2.38 | (1.19-4.77) | .014 | |
| Multivariate | ||||||
| TKI type | ||||||
| Imatinib 400† | 69 | 21 | ||||
| Imatinib 800 | 199 | 38 | 0.55 | (0.32-0.94) | .030 | |
| Dasatinib | 104 | 7 | 0.28 | (0.12-0.67) | .004 | |
| Nilotinib | 108 | 11 | 0.44 | (0.21-0.92) | .029 | |
| Transcript type | ||||||
| e13a2‡ | 199 | 40 | ||||
| e14a2 | 196 | 24 | 0.59 | (0.36-0.98) | .043 | |
| Both | 85 | 13 | 0.80 | (0.43-1.50) | .489 | |
| Splenomegaly (≥10 cm) | ||||||
| No | 453 | 68 | ||||
| Yes | 27 | 9 | 2.18 | (1.07-4.44) | .031 |
| . | N . | Events . | Log-rank . | HR . | 95% CI HR . | P value . |
|---|---|---|---|---|---|---|
| Univariate* | ||||||
| TKI type | ||||||
| Imatinib 400† | 69 | 21 | 0.013 | |||
| Imatinib 800 | 199 | 38 | 0.58 | (0.34-0.99) | .045 | |
| Dasatinib | 104 | 7 | 0.28 | (0.12-0.67) | .004 | |
| Nilotinib | 108 | 11 | 0.45 | (0.22-0.95) | .035 | |
| Transcript type | ||||||
| e13a2‡ | 199 | 40 | 0.091 | |||
| e14a2 | 196 | 24 | 0.57 | (0.35-0.95) | .032 | |
| Both | 85 | 13 | 0.74 | (0.40-1.39) | .355 | |
| Splenomegaly (≥10 cm) | ||||||
| No | 453 | 68 | 0.012 | |||
| Yes | 27 | 9 | 2.38 | (1.19-4.77) | .014 | |
| Multivariate | ||||||
| TKI type | ||||||
| Imatinib 400† | 69 | 21 | ||||
| Imatinib 800 | 199 | 38 | 0.55 | (0.32-0.94) | .030 | |
| Dasatinib | 104 | 7 | 0.28 | (0.12-0.67) | .004 | |
| Nilotinib | 108 | 11 | 0.44 | (0.21-0.92) | .029 | |
| Transcript type | ||||||
| e13a2‡ | 199 | 40 | ||||
| e14a2 | 196 | 24 | 0.59 | (0.36-0.98) | .043 | |
| Both | 85 | 13 | 0.80 | (0.43-1.50) | .489 | |
| Splenomegaly (≥10 cm) | ||||||
| No | 453 | 68 | ||||
| Yes | 27 | 9 | 2.18 | (1.07-4.44) | .031 |
White blood cell count, age, Sokal score, hemoglobin, platelet count, peripheral blood blasts, and serum lactate dehydrogenase are not significant (P = not significant; data not shown).
Imatinib 400 is the reference for comparison with the other 3 TKI modalities.
e13a2 is the reference for comparison with e14a2 and both (coexpressed transcripts).